AmCad BioMed Corporation AI Stock Analysis
AmCad BioMed Corporation (4188) AI Stock Analysis
AmCad BioMed Corporation
(TPEx:4188)
AmCad BioMed scores poorly overall, driven primarily by deteriorating fundamentals: revenue has more than halved since 2021 and fell ~43% in the latest year, gross margin dropped from ~62% to ~33%, net losses widened to NT$55.7m, and the company burned roughly NT$47m of free cash flow for a sixth consecutive year. A debt-free balance sheet with NT$521m of equity provides meaningful runway and keeps near-term solvency risk low, but accumulated losses are steadily depleting that cushion. Valuation provides no cushion either, with a negative P/E and no dividend. The main partial offset is the technical picture: the stock still trades above its 100- and 200-day moving averages with a positive MACD, though neutral RSI and a weak stochastic reading point to short-term consolidation rather than renewed strength. Investors should look for stabilization in revenue and gross margin before the fundamental risk profile improves.
AmCad BioMed Corporation (4188) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 851.83M
- Dividend Yield
- ―
- Average Volume (3M)
- 340.10K
- Price to Earnings (P/E)
- -15.0
- Beta (1Y)
- 0.53
- Revenue Growth
- -39.87%
- EPS Growth
- -14.87%
- Country
- TW
- Employees
- 69,576
- Sector
- General
- Sector Strength
- 55
- Industry
- Software - Application
AmCad BioMed Corporation Business Overview & Revenue Model
Company Description
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD de...
AmCad BioMed Corporation Financial Statement Overview
Summary
Fundamentals are weak. Revenue has shrunk from NT$85.8m in 2021 to NT$30.4m in 2025, including a ~43% decline in the latest year, while gross margin collapsed from ~62% to ~33%. The company has never been profitable in the period shown, with net losses widening to NT$55.7m and operating losses (NT$88.0m) exceeding total revenue. Free cash flow was -NT$47.4m, a sixth straight year of cash burn, and losses are genuine cash losses rather than accounting charges. The one clear offset is the balance sheet: debt-to-equity of roughly 0.01, NT$521.4m of equity against NT$622.7m of assets, and no refinancing risk — giving the company runway but an equity base that is steadily eroding (down from NT$568.7m in 2024) with ROE near -10.7%.
Income Statement
12Very NegativeBalance Sheet
68PositiveCash Flow
13Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.60M | 30.44M | 53.10M | 65.26M | 61.63M | 85.79M |
| Gross Profit | 10.33M | 10.02M | 32.93M | 41.02M | 38.05M | 60.66M |
| EBITDA | -66.58M | -55.52M | -34.41M | -25.56M | -36.60M | -8.46M |
| Net Income | -56.98M | -55.72M | -50.58M | -45.31M | -53.49M | -25.54M |
Balance Sheet | ||||||
| Total Assets | 617.38M | 622.70M | 694.87M | 512.65M | 553.86M | 615.75M |
| Cash, Cash Equivalents and Short-Term Investments | 341.88M | 371.22M | 365.71M | 287.27M | 330.84M | 371.05M |
| Total Debt | 13.35M | 4.75M | 10.87M | 14.50M | 10.49M | 14.80M |
| Total Liabilities | 29.33M | 21.88M | 31.16M | 34.70M | 34.08M | 36.72M |
| Stockholders Equity | 515.55M | 521.42M | 568.65M | 380.58M | 424.58M | 482.98M |
Cash Flow | ||||||
| Free Cash Flow | -47.43M | -47.44M | -54.90M | -41.89M | -34.81M | -41.30M |
| Operating Cash Flow | -47.31M | -47.06M | -51.85M | -41.60M | -34.19M | -38.97M |
| Investing Cash Flow | 58.21M | 58.93M | -185.43M | 27.31M | 27.14M | 49.18M |
| Financing Cash Flow | -4.76M | -5.02M | 225.38M | -3.10M | -4.42M | -11.35M |
AmCad BioMed Corporation Peers Comparison
Overall Rating
- TW:418845Neutral
TW:417140Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4188 | AmCad BioMed Corporation | 13.45 | -2.45 | -15.41% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.50 | -5.50 | -26.19% | |
| TW:6810 | Bio Preventive Medicine Corp. | 22.75 | -1.75 | -7.14% | |
| TW:6850 | Bioptic Inc. | 27.65 | -12.75 | -31.55% | |
| TW:6879 | Tci Gene Inc. | 35.50 | -3.65 | -9.32% | |
| TW:7725 | LabTurbo Biotech Corporation | 21.00 | -1.81 | -7.93% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026